Disease Landscape and Forecast Insights

In This Increasingly Crowded Setting, What Key Attributes Will Differentiate Emerging Therapies According to Oncologists and Payers? Treatment decisions for non-small-cell lung cancer (NSCLC)…

What Advantages Do Surveyed Oncologists and Payers Believe Emerging Therapies Must Offer to Gain Traction in This Market? The introduction of the HER2-targeting agent trastuzumab (Roche/…

Idiopathic pulmonary fibrosis (IPF), although a rare disease, is one of the most common interstitial lung diseases (ILDs) and is characterized by irreversible loss of lung function leading to high…

A Survey of Noninterventional Cardiologists, Endocrinologists, and Managed Care Organization Pharmacy and Medical Directors The primary goal of therapy for individuals with dyslipidemia is to…

How Can Emerging Augmentation Strategies Be Differentiated to Maximize Uptake in a Mature and Genericized Market? Unipolar depression, which includes major depressive disorder (MDD), minor…

TreatmentTrends: Diabetic Retinopathy/Diabetic Macular Edema 2015 (US) is the fourth annual syndicated report series that offers a snapshot of DR and DME market dynamics and the competitive…

What Improvements Do Physicians and Payers Expect from Emerging Therapies? Owing to a lack of specific symptoms, the majority of patients with ovarian cancer (CaO) present at an advanced stage…

What Attributes Will Distinguish Emerging Therapies, According to Physicians and Payers? Targeted therapies, particularly tyrosine kinase inhibitors (TKIs) that target angiogenesis, dominate the…

Can Targeting Patient Subpopulations Serve as a Market Access Lever? The asthma market is dominated by a number of effective and well-established treatments, including inhaled and oral therapies…

As Anti-NGF Therapies Resume Phase III Trials, What Attributes of Emerging Therapies Will Most Influence Physician and Payer Decisions? Osteoarthritis (OA) is a tremendously prevalent condition…

How Receptive Are Ophthalmologists and U.S. Payers to Emerging Therapies in This Underserved Market? Affecting more than 40 million people in its severe form, dry eye disease represents a large…

Physician and Payer Expectations for Changes in Treatment Algorithms Monoclonal antibodies (MAbs) have become the standard of care in the treatment of non-Hodgkin’s lymphoma (NHL), colorectal…